| Balance sheet (USD) | Q4 2026 ended May 31, 2026 | Q3 2026 ended Feb 28, 2026 | Q2 2026 ended Nov 30, 2025 | Q1 2026 ended Aug 31, 2025 | Q4 2025 ended May 31, 2025 | Q3 2025 ended Feb 28, 2025 | Q2 2025 ended Nov 30, 2024 | Q1 2025 ended Aug 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 53.86M | 37.81M | 41.64M | 38.76M | 55.89M | 44.76M | 54.09M | 55.01M |
| Receivables | 48.33M | 45.55M | 44.43M | 42.64M | 42.89M | 43.47M | 43.16M | 39.56M |
| Inventory | 52.44M | 58.58M | 65.57M | 62.26M | 62.01M | 63.10M | 65.92M | 64.70M |
| Total current assets | 163.39M | 155.55M | 161.35M | 156.66M | 168.32M | 172.27M | 175.36M | 172.59M |
| Property, plant and equipment | 27.10M | 29.14M | 30.53M | 31.07M | 32.30M | 32.53M | 32.98M | 34.38M |
| Goodwill and intangibles | 67.21M | 65.49M | 66.73M | 68.38M | 69.12M | 70.93M | 73.11M | 75.77M |
| Total assets | 267.16M | 260.68M | 269.68M | 265.64M | 280.14M | 285.42M | 291.55M | 293.63M |
| Accounts payable | 31.51M | 29.11M | 35.39M | 31.88M | 33.29M | 30.27M | 34.75M | 31.27M |
| Total current liabilities | 74.72M | 66.07M | 71.96M | 68.28M | 76.20M | 77.97M | 88.59M | 76.70M |
| Total liabilities | 96.34M | 87.32M | 93.35M | 86.79M | 97.17M | 99.55M | 104.78M | 97.05M |
| Retained earnings | -465.94M | -454.53M | -446.45M | -440.10M | -429.20M | -423.15M | -418.74M | -408.00M |
| Shareholders' equity | 170.82M | 173.36M | 176.33M | 178.85M | 182.97M | 185.87M | 186.77M | 196.58M |
From Angiodynamics Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.